Fate Therapeutics Inc Shares Close the Week 27.4% Higher - Weekly Wrap
The company saw its shares close the week 27.4% higher than last week, with trading volume higher than its 30 day average.
Jun 24, 2022 by Kwhen Finance Editors
Fate Therapeutics Inc (FATE) shares closed this week 27.4% higher than it did at the end of last week. The stock is currently down 54.2% year-to-date, down 68.4% over the past 12 months, and up 742.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.5%, and the S&P 500 rose 3.6%.
Trading Activity
- Shares traded as high as $26.86 and as low as $19.55 this week.
- Shares closed 72.5% below its 52-week high and 56.7% above its 52-week low.
- Trading volume this week was 36.4% lower than the 10-day average and 20.4% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 2.1.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
- The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis
Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
---|---|---|---|---|---|
Fate Therapeutics Inc | 4.6 | -54.2 | -68.4 | -73.3 | 52.2 |
Dow Jones Industrial Average | 2.7 | -14.8 | -7.8 | -15.5 | 4.3 |
S&P 500 Index | 3.2 | -19.8 | -9.3 | -19.9 | 5.3 |
Health Care | 1.6 | -9.2 | 1.1 | -10.6 | 8.9 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 605.9%
- The company's stock price performance over the past 12 months lags the peer average by 512.7%
Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
---|---|---|---|---|---|---|
Fate Therapeutics Inc | FATE | -11.1 | -54.2 | -68.4 | -73.3 | 52.2 |
Peer Avg | N/A | 29.1 | -7.7 | -11.2 | -22.0 | 32.6 |
Becton, Dickinson And Co. | BDX | 39.1 | 2.9 | 8.7 | -10.8 | 8.6 |
Neurocrine Biosciences, Inc. | NBIX | 130.4 | 14.4 | -2.9 | -8.9 | 36.9 |
Sarepta Therapeutics Inc | SRPT | -18.5 | -16.5 | -5.6 | -30.4 | 15.0 |
PTC Therapeutics Inc | PTCT | -5.5 | 1.0 | -8.9 | -12.2 | 60.7 |
Avidity Biosciences Inc | RNA | 0 | -40.2 | -47.2 | -47.8 | 41.9 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: